Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease

Area of Science:

• Cardiology
• Biochemistry
• Inflammation Research

Background:

• Unstable coronary artery disease (CAD) involves complex thrombotic and inflammatory processes.
• Understanding the dynamics of inflammatory markers is crucial for risk stratification in unstable CAD.

Purpose of the Study:

• To assess the time-course of fibrinogen and C-reactive protein (CRP) levels in unstable CAD.
• To evaluate the impact of thrombin inhibitors on these markers.
• To correlate marker levels with myocardial ischemia and patient outcomes.

Main Methods:

• A randomized trial involving 320 patients with unstable CAD.
• Infusion of inogatran (direct thrombin inhibitor) or unfractionated heparin for 72 hours.
• Measurement of fibrinogen and CRP levels at various time points.
• Assessment of troponin status and clinical outcomes (death, myocardial infarction).

Main Results:

• No significant differences in fibrinogen or CRP between treatment groups.
• Fibrinogen levels increased significantly within 24-96 hours and remained elevated at 30 days.
• C-reactive protein (CRP) levels peaked within 24-96 hours and then decreased by 30 days.
• Troponin-positive patients showed higher fibrinogen and CRP levels up to 96 hours.
• High baseline fibrinogen was associated with increased 30-day death/myocardial infarction and long-term mortality.
• High CRP was linked to increased 30-day mortality.

Conclusions:

• Myocardial injury in unstable CAD is linked to significant inflammation, partly an acute-phase response.
• Sustained fibrinogen elevation may indicate chronic low-grade inflammation and long-term thrombotic risk.
• Transient CRP elevation suggests a propensity for pronounced inflammation and is associated with higher mortality.